

Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura

<http://guidance.nice.org.uk/TA/Wave17/16>

Dear Consultees and Commentators,

The NICE Technology Appraisal Committee considered this appraisal on 1 April 2009. The release of the Appraisal Consultation Document (ACD, the draft guidance) was delayed until the price of romiplostim had been announced by the manufacturer. The ACD was issued to you in October 2009.

In December 2009 we informed you that the manufacturer had submitted a Patient Access Scheme and that this scheme would need to be formally approved by the Department of Health. The appraisal was therefore rescheduled.

We can now proceed with this appraisal. It will be discussed by the Committee on **2 September 2010**. We will invite the clinical and patient experts back to this meeting.

If you have any questions, please contact me.

Kind regards,

Jeremy

Jeremy Powell

Technology Appraisal Project Manager

National Institute for Health and Clinical Excellence

MidCity Place | 71 High Holborn | London WC1V 6NA | United Kingdom

Tel: 44 (0)20 7045 2248 | Fax: 44 (0)20 7061 9830

Web: <http://nice.org.uk>